Published in J Vitreoretin Dis on January 26, 2017
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol (2004) 18.86
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology (2010) 7.30
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology (2009) 6.44
Age-related macular degeneration. Lancet (2012) 4.17
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology (2014) 3.50
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol (2011) 2.80
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci (2000) 2.38
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol (2013) 2.32
Choroidal neovascularization. Am J Ophthalmol (2004) 2.18
Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology (1999) 2.10
Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol (1992) 2.04
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina (2006) 1.91
Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol (2007) 1.88
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (2009) 1.67
Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology (2013) 1.63
Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina (2007) 1.52
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) (2013) 1.49
Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res (2005) 1.40
Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci (2003) 1.29
The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis (1999) 1.18
Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res (2005) 1.15
Disparities in adult vision health in the United States. Am J Ophthalmol (2012) 1.12
Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis (2003) 1.10
Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol (2013) 1.08
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology (2012) 1.05
Genetics of immunological and inflammatory components in age-related macular degeneration. Ocul Immunol Inflamm (2012) 1.04
Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol (2014) 1.00
Sustained-release corticosteroid options. J Ophthalmol (2014) 0.99
Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res (2009) 0.91
Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Can J Ophthalmol (2012) 0.87
Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation (1997) 0.86
LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. Retina (2013) 0.84
Sodium hyaluronate gels as a drug-release system for corticosteroids: release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol (2008) 0.83
Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration. Ophthalmic Res (2010) 0.81
Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment. Eur J Pharm Biopharm (2010) 0.80
Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. Ophthalmologica (2015) 0.76
Screening and treatments using telemedicine in retinopathy of prematurity. Eye Brain (2016) 0.75